Can A Man Be Too Young For Active Surveillance in Management of Low-Rise Prostate Cancer?

Thursday, August 25, 2016
There is a “conventional wisdom” that careful monitoring through so-called “active surveillance” as a way to manage low-risk prostate cancer is only a good idea for older men in their 60s and 70s, and that younger men with low-risk prostate cancer are better off having immediate radical treatment. By “better off” we mean that there’s a better chance at cancer control, or that the common side effects of treatment, particularly incontinence and impotence, will be milder if treated earlier.

However, when one turns a spotlight on that conventional wisdom, it’s not so clear that it holds up under scrutiny.

For starters, it’s important to understand how slowly low-risk prostate cancer typically progresses in young men, even without active surveillance; that is, even without any intention to treat if the cancer progresses. Based on the Memorial Sloan-Kettering Cancer Center male life expectancy survey, we can see that for a 45-year-old man in excellent health diagnosed with a Gleason score of 3 + 3, a PSA of 4 ng/ml, and nothing felt on a digital rectal exam, he has a zero chance of dying of prostate cancer in the next 10 years, and a 4 percent chance of dying of something else. Even if he lets it go for 15 years, he still only has a 3 percent chance of dying of prostate cancer, and an 8 percent chance of dying of something else.

To read the full and detailed text of this article, please click here.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.